Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 2
2003 17
2004 8
2005 8
2006 4
2007 3
2008 3
2009 4
2010 1
2011 5
2012 6
2013 13
2014 7
2015 10
2016 11
2017 10
2018 11
2019 19
2020 18
2021 18
2022 18
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Rethinking breast cancer follow-up based on individual risk and recurrence management.
De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G. De Rose F, et al. Among authors: di cosimo s. Cancer Treat Rev. 2022 Sep;109:102434. doi: 10.1016/j.ctrv.2022.102434. Epub 2022 Jul 1. Cancer Treat Rev. 2022. PMID: 35933845 Free article. Review.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. Among authors: di cosimo s. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-De Dueñas E, Carañana V, Amillano K, Mina L, Malfettone A, Cortés J, Llombart-Cussac A. Di Cosimo S, et al. Oncologist. 2023 Jan 18;28(1):23-32. doi: 10.1093/oncolo/oyac205. Oncologist. 2023. PMID: 36239405 Free PMC article. Clinical Trial.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Pérez-García JM, et al. Among authors: di cosimo s. Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34019819 Clinical Trial.
DESTINY-Breast03 trial: some questions remain.
Di Cosimo S, Apolone G, Cappelletti V, Torri V. Di Cosimo S, et al. Lancet. 2023 May 20;401(10389):1653. doi: 10.1016/S0140-6736(23)00685-2. Lancet. 2023. PMID: 37210116 No abstract available.
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C. Ligorio F, et al. Among authors: di cosimo s. J Natl Cancer Inst. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126. J Natl Cancer Inst. 2022. PMID: 35789270
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, Sotiriou C. Rediti M, et al. Among authors: di cosimo s. Nat Commun. 2023 Nov 3;14(1):7053. doi: 10.1038/s41467-023-42635-2. Nat Commun. 2023. PMID: 37923752 Free PMC article. Clinical Trial.
microRNAs in breast cancer development and treatment.
Serpico D, Molino L, Di Cosimo S. Serpico D, et al. Among authors: di cosimo s. Cancer Treat Rev. 2014 Jun;40(5):595-604. doi: 10.1016/j.ctrv.2013.11.002. Epub 2013 Nov 14. Cancer Treat Rev. 2014. PMID: 24286642 Review.
Can we define breast cancer HER2 status by liquid biopsy?
Di Cosimo S, De Marco C, Silvestri M, Busico A, Vingiani A, Pruneri G, Cappelletti V. Di Cosimo S, et al. Int Rev Cell Mol Biol. 2023;381:23-56. doi: 10.1016/bs.ircmb.2023.07.003. Epub 2023 Sep 4. Int Rev Cell Mol Biol. 2023. PMID: 37739483 Review.
197 results